Amarin Corp Plc (AMRN)

[jessellivermore]

GM..

Actually the rule in most cases is the cheapest alternative is awarded the Tier one and in most cases that is the generic..The problem the generics face in this situation is there is more than one generic and both have the same indication and usage. In such cases the drug plans will go with the cheapest alternative and that will be gen Lovaza as it has been. As Vascepa is much more expensive to produce..This situation actually has been going on for some time..Its just it will not be Amarin vs Lovaza it will be Teva {if they make gen Lovaza} against Reddi and Hikma..

Most of the Amarin MB here has complained about how Lovaza has dominated Vascepa..The reason is/was the situation was that the drug plans look at the indications and usage on the label and then they go with the cheapest alternative. And that is why there was so many of Amarin scripts which were being converted to Lovaza or Gen Lovaza scripts..Remember up until late December last year the only label Amarin had was the MARINE label..

The same thing will happen to the generics unless they can sell gen Vascepa cheaper than gen Lovaza..(not likely)..The generics are prohibited from advertising or promoting their drug..Vascepa for CVD event reduction..And they can not go to the drug plans and tell them their drug actually reduces CVD events and that is why we are selling it..That would infringe on Amarin's patents that are still valid..

":>) JL